Update on Gavi support for Oral Cholera Vaccine (OCV)

GTFCC OCV WG meeting Adam Soble 3rd December 2020



Key Board decisions and developments for Gavi's OCV support

2018 2019 2020







- As part of Vaccine Investment Strategy (VIS), Gavi Board approved transition of the oral cholera vaccine programme to include a preventive immunisation programme, beginning in 2021¹
- Approved extension of Gavi support for use of the global cholera stockpile for preventive campaigns in cholera hotspots for 2020
- Approved funding for cholera learning agenda activities

- Gavi 5.0 approach assumed inclusion of VIS vaccine candidates in Gavi's portfolio to evaluate potential impact of different strategic options for 2021-2025 period
- Gavi Board approved Gavi 5.0 strategy which included transition of cholera support to preventive immunisation programme as part of new vaccine programme support recommended through VIS
- Due to COVID-19 pandemic, Gavi Board approved delay implementation of VIS programmes until after acute phase of pandemic
- Gavi Board being asked to approve extension of Gavi support for use of the global cholera stockpile in endemic settings through 2022²
- Implementation and support for Gavi preventive cholera immunisation programme to start no later than Jan. 2023
- L. Subject to availability of funding following Gavi replenishment and alignment with Gavi 5.0 in June 2019
- 2. In October 2020, the Gavi Programme and Policy Committee recommended Gavi's Board approve the extension of Gavi support for use of the global cholera stockpile in endemic settings through 2022